Eversept Partners LP Sells 108,115 Shares of Moderna, Inc. $MRNA

Eversept Partners LP lessened its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 40.4% in the first quarter, HoldingsChannel.com reports. The firm owned 159,708 shares of the company’s stock after selling 108,115 shares during the quarter. Eversept Partners LP’s holdings in Moderna were worth $8,113,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Canton Hathaway LLC acquired a new position in shares of Moderna in the 1st quarter worth approximately $31,000. Assetmark Inc. increased its position in shares of Moderna by 35.1% during the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after buying an additional 208 shares during the period. MUFG Securities EMEA plc acquired a new stake in shares of Moderna during the second quarter worth $28,000. Flagship Harbor Advisors LLC bought a new position in Moderna during the fourth quarter worth $31,000. Finally, Cromwell Holdings LLC raised its stake in Moderna by 39.7% during the fourth quarter. Cromwell Holdings LLC now owns 1,200 shares of the company’s stock worth $35,000 after buying an additional 341 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have commented on the stock. The Goldman Sachs Group upped their price target on shares of Moderna from $49.00 to $67.00 and gave the company a “neutral” rating in a research report on Tuesday, July 21st. UBS Group reissued a “neutral” rating on shares of Moderna in a research report on Tuesday, May 26th. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a research report on Thursday, June 18th. Barclays raised their target price on Moderna from $25.00 to $48.00 and gave the stock an “equal weight” rating in a research note on Thursday, April 2nd. Finally, Bank of America lifted their target price on Moderna from $34.00 to $38.00 and gave the stock an “underperform” rating in a report on Tuesday, July 7th. Two investment analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and five have issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Reduce” and a consensus price target of $40.00.

Moderna Stock Performance

MRNA opened at $55.63 on Tuesday. The company has a current ratio of 2.41, a quick ratio of 2.35 and a debt-to-equity ratio of 0.08. The company’s fifty day moving average price is $58.67 and its two-hundred day moving average price is $52.05. Moderna, Inc. has a 1-year low of $22.28 and a 1-year high of $85.60. The company has a market cap of $22.07 billion, a price-to-earnings ratio of -6.83 and a beta of 0.94.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, May 1st. The company reported ($3.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.02) by ($0.38). The business had revenue of $389.00 million for the quarter, compared to analyst estimates of $236.37 million. Moderna had a negative net margin of 143.55% and a negative return on equity of 26.64%. The firm’s quarterly revenue was up 260.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($2.52) earnings per share. On average, analysts expect that Moderna, Inc. will post -6.41 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of Moderna stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the completion of the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. The trade was a 3.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Noubar Afeyan sold 9,263 shares of the business’s stock in a transaction that occurred on Thursday, May 21st. The stock was sold at an average price of $46.84, for a total value of $433,878.92. Following the sale, the director directly owned 3,924 shares of the company’s stock, valued at $183,800.16. This represents a 70.24% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 125,088 shares of company stock worth $6,193,713 in the last quarter. 10.80% of the stock is owned by insiders.

Moderna Company Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company’s platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna’s flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.